NICE is unable to make a recommendation about the use in the NHS of tabelecleucel for treating post‑transplant lymphoproliferative disorder caused by the Epstein‑Barr virus. This is because Pierre Fabre Ltd has confirmed that it does not intend to make an evidence submission for the appraisal at this time and will review this at a later date.
If NHS organisations wish to consider tabelecleucel for this indication, they should follow the advice on rational local decision making in the NHS Constitution for England and the NHS Commissioning Board and Clinical Commissioning Groups (Responsibilities and Standing Rules) Regulations 2012. This outlines the approach that should be taken when there is no NICE guidance.
NICE will review the position if the company decides that it wants to make an evidence submission.